After platinum-based chemoradiotherapy, a consolidation immunotherapy regimen significantly improved overall survival (OS) in patients with limited-stage small cell lung cancer (SCLC), an outcome that is expected to provide the first major standard-of-care change in decades. The data were presented as a late-breaker study at the 2024 annual meeting of the American Society of Clinical Oncology (LBA5).
Unlike the role that immunotherapy now plays in non-SCLC and, more recently, metastatic SCLC,